Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.

Abstract

PURPOSE Most patients with chronic lymphocytic leukemia (CLL) are elderly and/or have comorbidities that may make them ineligible for fludarabine-based treatment. For this population, chlorambucil monotherapy is an appropriate therapeutic option; however, response rates with chlorambucil are low, and more effective treatments are needed. This trial was… (More)
DOI: 10.1200/JCO.2013.49.6547

Topics

Cite this paper

@article{Hillmen2014RituximabPC, title={Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.}, author={Peter Hillmen and John G Gribben and George Alexander Follows and Donald W. Milligan and Hazem A Sayala and Paul Moreton and David Oscier and Claire E. Dearden and Daniel B. Kennedy and Andrew R. Pettitt and Amit Chunilal Nathwani and Abraham M Varghese and Dena R. Cohen and Andy C Rawstron and Stephan H Oertel and Christopher F E Pocock}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2014}, volume={32 12}, pages={1236-41} }